Pfizer’s RSV Vaccine Springs Another Surprise, This Time In Maternal Use
Could Seize Share From Sanofi - Analysts
Executive Summary
Sanofi’s monoclonal antibody is still expected to lead the market in respiratory syncytial virus, but Pfizer may have just overturned expectations about maternal vaccination with its product.
You may also be interested in...
Pfizer Anticipates A 'Bolus Of Revenue' From RSV, Prevnar 20 Launches This Year
Biopharmaceuticals president Angela Hwang said the company is anticipating a strong fourth quarter, driven by the launch of an RSV vaccine and expansion of Prevnar 20 for pediatric use.
Pfizer Plans For COVID Transition And RSV Vaccine Launch
The COVID-19 vaccine and treatment market is expected to evolve into more a flu-like volume and market in 2023, but will remain a "multi-billion dollar" franchise, Bourla said.
Pfizer’s RSV Vaccine Shows Efficacy In Older Adults, Setting Up Showdown With GSK
Pfizer’s bivalent vaccine candidate showed efficacy in RSV patients with multiple respiratory infection symptoms and may offer protection against the A and B strains of the virus.